RxDoctor Payments DataLook up a doctor →

Pablo Perez, MD

Internal Medicine · Dalton, GANPI 1942218086

Payments from drug & device makers

$235,729in general payments, 2019–2025

Across 659 payments — averaging $357.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$101K
  • Bausch Health US, LLC$49K
  • Boehringer Ingelheim$32K
  • Boehringer Ingelheim Canada Ltd.ltee$22K
  • Karyopharm Therapeutics Inc.$15K
  • Novo Nordisk$3K
  • plus $14K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Endo Pharmaceuticals Inc.18$100,898
Bausch Health US, LLC27$48,910
Boehringer Ingelheim17$31,623
Boehringer Ingelheim Canada Ltd.ltee33$21,591
Karyopharm Therapeutics Inc.2$15,000
Novo Nordisk48$3,292
AstraZeneca64$2,469
Eli Lilly2$2,311
Lilly USA, LLC81$1,427
AbbVie(2 entities)78$1,331
Amgen(2 entities)57$924
Sanofi-aventis U.S. LLC31$613
Bayer10$571
Axsome Therapeutics, Inc.5$373
Phathom Pharmaceuticals, Inc.5$362
Amarin Pharma, Inc.23$339
Abbott11$331
GSK16$327
Corcept Therapeutics10$271
Esperion Therapeutics, Inc.6$234
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$234
Kowa Pharmaceuticals America, Inc.10$217
Merck13$197
Astellas Pharma US Inc4$184
Takeda Pharmaceuticals U.S.A., Inc.8$158
Dexcom, Inc.3$150
Valeritas, Inc.1$120
Shield Therapeutics Inc5$111
Otsuka America Pharmaceutical, Inc.2$108
Neurocrine Biosciences, Inc.1$101
Sumitomo Pharma America, Inc.5$89
Pfizer5$83
Novartis4$70
Radius Health, Inc.3$58
Johnson & Johnson4$49
Lundbeck LLC2$48
Change Healthcare Technologies, LLC1$43
Eisai Inc.3$41
Idorsia Pharmaceuticals US Inc2$39
Alfasigma USA, Inc.2$38
Insulet Corporation2$38
Xeris Pharmaceuticals, Inc.2$31
Sunovion Pharmaceuticals Inc.2$30
Paratek Pharmaceuticals, Inc.2$28
Mannkind Corporation2$25
Organon1$23
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$23
Madrigal Pharmaceuticals1$22
Genentech USA, Inc.1$19
Ascend Therapeutics US, LLC1$18
Medtronic1$18
Shire North American Group Inc1$18
Ascendis Pharma Endocrinology Inc1$17
VBI Vaccine (delaware) Inc.1$16
Boston Scientific1$15
Lexicon Pharmaceuticals, Inc.1$14
Linus Health, Inc.1$13
Biohaven Pharmaceutical Holding Company Ltd.1$13
Scilex Pharmaceuticals Inc.1$13

How this compares

$235,729 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia →

Medicare billing

Part B allowed, 2024
$151,838
Medicare patients
312
Services billed
2,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Dalton

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →